About: Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.68 (-3.88%)
HELP NYSE Helus Pharma Inc.
Helus Pharma Inc. share price
Atividade de preço de HELP
Último preço
$ 8,680
Variação (24h)
-0,35 USD (3,88%)
Volume
1.24M
Volume (média 4 sem.)
-
Abertura
$ 9,03
Variação do dia
$ 8,56 - $ 9,33
Fechamento anterior
$ 9,03
Último negócio
04 Nov, 9:22 pm GMT+0
Atrasado
04 Nov, 9:22 pm GMT+0
HELP price performance
Atrasado
04 Nov, 9:22 pm GMT+0
HELP details
quote.marketSignals